The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,088, titled ...

SAN DIEGO -- Sparsentan effectively reduced proteinuria after 8 weeks in patients with focal segmental glomerulosclerosis (FSGS), a rare and progressive kidney disorder, according to results from a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Please provide your email address to receive an email when new articles are posted on . Absolute overall change in kidney function for patients treated with sparsentan was –5.8 mL/min/1.73 m 2.

The FDA expanded the indication of sparsentan (Filspari) to make it the first treatment for focal segmental glomerulosclerosis (FSGS), developer Travere Therapeutics announced on Monday. A once-daily ...

Credit: Getty Images. Investigators reported findings from the phase 3 PROTECT and DUPLEX trials. Sparsentan achieves more pronounced reductions in proteinuria in patients with immunoglobulin A ...

Please provide your email address to receive an email when new articles are posted on . At 36 weeks, patients receiving sparsentan experienced a mean 49.8% reduction in proteinuria from baseline.

SAN DIEGO — Travere Therapeutics, a biotech focused on treating rare diseases, on Monday announced that a Phase 3 trial of an experimental treatment for focal segmental glomerulosclerosis, a rare and ...

The Food and Drug Administration (FDA) has extended the review period for sparsentan in focal segmental glomerulosclerosis (FSGS). Sparsentan, an oral endothelin and angiotensin II receptor antagonist ...

First non-immunosuppressive dual-action therapy approved for eligible patients The National Institute for Health and Care Excellence (NICE) has recommended FILSPARI (sparsentan) for use in the NHS in ...